You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 281 No. 3, January 20, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (18)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in JAMA
 Topic Collections
 •Obesity
 •Alert me on articles by topic

Pharmacotherapy for Obesity

David F. Williamson, PhD

JAMA. 1999;281:278-280.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In the summer of 1957, my pediatrician became so concerned about my weight that he convinced my mother that I should begin taking pills to curb my appetite. I was 7 years old and weighed 70 pounds with a goal of reaching 60 pounds. I still remember how those pills made me feel; I had no appetite and felt chronically anxious. Most remarkable to me that summer was that my hands were always cold. I did reach my target weight but the chronic anxiety continued and the pills were stopped. I promptly regained all the weight that I had lost.

Since my childhood in the 1950s obesity has become substantially more prevalent in the United States,1 despite high levels of reported efforts to lose weight.2 Paradoxically, over this same period, total and cardiovascular mortality have decreased, along with the prevalence of hypertension and hypercholesterolemia.3 Such trends . . . [Full Text of this Article]

Author Affiliation: Division of Diabetes Translation (K-68), Centers for Disease Control and Prevention, Atlanta, Ga.


RELATED ARTICLES

Weight Control and Risk Factor Reduction in Obese Subjects Treated for 2 Years With Orlistat: A Randomized Controlled Trial
Michael H. Davidson, Jonathan Hauptman, Mario DiGirolamo, John P. Foreyt, Charles H. Halsted, David Heber, Douglas C. Heimburger, Charles P. Lucas, David C. Robbins, Jain Chung, and Steven B. Heymsfield
JAMA. 1999;281(3):235-242.
ABSTRACT | FULL TEXT  

Maintaining a healthy weight
JAMA. 1999;281(3):296.
PDF  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Efficacy and Safety of Sibutramine for Weight Loss: A Systematic Review
Arterburn et al.
Arch Intern Med 2004;164:994-1003.
ABSTRACT | FULL TEXT  

The Effect of Orlistat-Induced Weight Loss, Without Concomitant Hypocaloric Diet, on Cardiovascular Risk Factors and Insulin Sensitivity in Young Obese Chinese Subjects With or Without Type 2 Diabetes
Tong et al.
Arch Intern Med 2002;162:2428-2435.
ABSTRACT | FULL TEXT  

Abdominal obesity and the "hypertriglyceridaemic waist" phenotype
Little and Byrne
BMJ 2001;322:687-689.
FULL TEXT  

Treatment of obesity: need to focus on high risk abdominally obese patients
Després et al.
BMJ 2001;322:716-720.
FULL TEXT  

Obesity and Hypertension: What Should We Do?
Pickering
ANN INTERN MED 2001;134:72-74.
FULL TEXT  

Orlistat in the Long-term Treatment of Obesity in Primary Care Settings
Hauptman et al.
Arch Fam Med 2000;9:160-167.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.